ICTM logo
HIVDRD
UK HIV Drug Resistance Database
Bringing together information to understand more about drug resistance in HIV
What is this study about?

The study was coordinated by CTU until 2016 and is now run from the UCL Research Department of Infection and Population Health.

The introduction of highly-active antiretroviral therapy (HAART) in the mid 1990s has led to a reduction in deaths and an improvement in HIV patients’ health and quality of life. But the HIV virus can mutate (or change) and become resistant to different drugs, which can limit treatment options.

Resistance tests are carried out in patients who show signs of failing their drug regimen and now, as a result of the findings of the Database, pre-therapy testing is routine practice.

The UK HIV Drug Resistance Database brings together information collected from all these HIV drug resistance tests carried out in the UK. This helps researchers to:

  • Understand how resistance testing can help doctors to treat people with HIV more effectively
  • Estimate how widespread drug resistance is, and how this changes over time
  • Look at how different mutations of the HIV virus affect drug resistance

The Database is unique because it is extensively linked with patient data within several clinical cohorts in the UK, which means that analyses can be performed that give important insights into the epidemiology and clinical aspects of HIV drug resistance.

The findings of the Database are important in understanding the epidemiology of transmitted drug resistance. Analyses carried out on drug-naïve patients give insights into transmitted drug resistance (TDR). Analyses on drug-experienced patients indicate the extent of resistance within and across drug classes and estimates of the number of individuals with multi-class resistance. All of these data are vital for the clinical management of HIV at a local and national level.

Who is included?

The database brings together information from all routine drug resistance tests that are carried out in all virology laboratories that are based in the NHS and in universities.

Contact details

When is it taking place?

This study began in 2001 and is ongoing.

Where is it taking place?

The study was coordinated by CTU until 2016 and is now run from the UCL Research Department of Infection and Population Health.

Who is funding the study?

Primary funding is provided by the Medical Research Council. The study was originally established through funding from the Department of Health. Additional funding has been provided by Bristol-Myers Squibb, Gilead, Pfizer, Roche, and Tibotec, a division of Janssen-Cilag Ltd.

Further information


Type of study:
Observational study
Status:
Open to recruitment
Study start date:
01 June 2001

Related Publications

on behalf of the TenoRes Study Gro.

Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infectious Diseases. 2016; 16:565-575-565-575

Mulenga, V., Musiime, V., Ketitiinwa, A., Cook, A., Abongomera, G., Kenny, J., Chabala, C., Mirembe, G., Asiimwe, A., Owen-Powell, E., Burger, D., McIlleron, H., Klein, N., Chintu, C., Thomason, M., Kityo, C., Walker, A.S., Gibb, D.M., on behalf of the CHAPAS-3 trial te.

Abacavir, zidovudine or stuvudine as 'baby pills' for African HIV-infected children: the CHAPAS-3 randomised controlled trial. Lancet Infectious Diseases. 2016; 16:169-179-169-179

Jose, S., Quinn, K., Dunn, D., Cox, A., Sabin, C., Fidler, S., for the UK CHIC and UK HDRD Study Committe.

Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Medicine. 2016; 17:368-372-368-372

Cairns, G., McCormack, S., Molina, J.

The European preexposure prophylaxis revolution. Current Opinion in HIV and AIDS. 2016; 11:74-79-74-79

Baeten, J., McCormack, .

Welcome to the preexposure prophylaxis revolution. Current Opinion in HIV and AIDS. 2016; 11:1-2-1-2